Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges
The promise of human induced pluripotent stem cells (iPSCs) lies in their ability to serve as a starting material for autologous, or patient-specific, stem cell–based therapies. Since the first publications describing the generation of iPSCs from human tissue in 2007, a Phase I/IIa clinical trial te...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Blackwell Publishing Inc.
2021
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |